Inactive
Last updated: April 9, 2025

TU + ENG

Testosterone Undecanoate (TU) + Etonogestrel (ENG)

  • User: Male
  • Hormonal: Hormonal
  • Delivery type:
    • Multiple
    • Injectable
    • Subdermal
  • Intended Duration:
    • Short-Acting
  • Development Stage: Phase II
  • Developer(s)/researcher(s): Organon
Details
  • API: Testosterone Undecanoate, Etonogestrel
  • Target: Progesterone Receptor, Androgen Receptor
  • Mechanism of Action:
    • Reduced Sperm Production
  • Inactive Materials: Undetermined
  • Regimen: Undetermined
  • MPT: Not Potential MPT
Product Status

After results of the 2006 study were published in 2008, no additional research was completed. 2008 results continue to be broadly cited.

History

A Phase IIb, placebo-controlled trial investigating the efficacy, safety and pharmacokinetics of the product was completed in 2006. This combination has been extensively evaluated by multiple development groups. However, no development is active. 

Publications